Experimental antibody IC14 tested in rare heart condition

NCT ID NCT06275893

Completed Disease control Sponsor: Implicit Bioscience Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested IC14 (atibuclimab), an antibody that targets inflammation, in one person with arrhythmogenic cardiomyopathy (ACM), a rare heart muscle disease that can cause dangerous heart rhythms. The study measured safety, blood markers of inflammation, and heart rhythm changes using the participant's implanted defibrillator and other tests. Because it involved only one participant and no placebo, the results are very preliminary.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IC14 (atibuclimab), a lab-made antibody targeting inflammation
What this could lead to: If it works, this could point toward a treatment that reduces inflammation and heart rhythm problems in people with arrhythmogenic cardiomyopathy.
What could go wrong: This is a very early, tiny trial with only 1 participant and no placebo group. It mainly checks safety, not effectiveness, so results may not apply to others.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute chest syndrome Arrhythmias, Cardiac arrhythmogenic right ventricular cardiomyopathy arrhythmogenic right ventricular dysplasia 1 arrhythmogenic right ventricular dysplasia 9 Arrhythmogenic Right Ventricular Dysplasia, Familial, 1 familial isolated arrhythmogenic ventricular dysplasia, left dominant form

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACM ARRHYTHMOGENIC CARDIOMYOPATHY ARRHYTHMOGENIC LEFT VENTRICULAR CARDIOMYOPATHY ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY 1 ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA ARVC PKP2

Contacts and locations

Locations

Cleveland Clinic

Cleveland, Ohio, 44195, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.